Day 1 - Wednesday, 28 October 2020
Meeting category
Date(s)
28 Oct 2020 - 30 Oct 2020
Organizer
Platinum Level Support
Sponsor logos
European Meeting on HIV & Hepatitis 2020
Related Enduring Materials
Enduring Materials
Preliminary Program
Opening session - 14:00
14:00 CEST
Opening of the Meeting
Anne-Geneviève Marcelin, MD
Hôpital Pitié-Salpétrière Paris, France
14:05 CEST
Andrea De Luca Lecture: The Top 10 Important Observations of the Last Year Affecting Clinical Management
Session 1: Challenges in Central and Eastern Europe -
Anca Streinu-Cercel, MD, PhD
Chair
Anne-Mieke Vandamme, MD, PhD
University of Leuven, Belgium
14:25 CEST
Epidemiology of HIV and Hepatitis in CEE
14:40 CEST
Transmitted and Acquired Resistance: Special Populations
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
14:55 CEST
Abstract - Driven Presentations
Infection with subtype D adversely affects the live expectancy among people living with HIV – data from Northwestern Poland
Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland
HIV Trace VS Phylogenetic Analysis: Unraveling Transmission Clusters in Spain
Federico Garcia - Hospital Universitario San Cecilio, Spain
Prevalence and evolution of transmitted HIV drug resistance in Belgium between 2013 and 2019
Virginie Mortier - University Hospital Gent, Belgium
Special Session: First Day Treatment – the European Perspective - 16:00
16:00 CEST
First Day Treatment, Definition, and Review of Data
16:15 CEST
Implementing First Day Treatment in Europe: Western Perspective
16:30 CEST
Implementing First Day Treatment in Europe: Central and Eastern Perspective
Session 2: Patient-Reported Outcomes and Studies -
Chair
Gary Rubin， MD
University of Toronto, Canada
17:10 CEST
Patient-Reported Outcomes and Studies
Abstract - Driven Presentations
Factors associated with the emergence of resistance mutations in patients failing dual or triple-integrase inhibitors-based regimen in a French national survey
Anne-Geneviève Marcelin, MD, PhD - France
HIV DNA DRUG RESISTANCE GENOTYPING, BASED ON ILLUMINA SEQUENCING, AS DECISIONAL MARKER FOR cART OPIMISATION IN CLINICAL PRACTICE: ADDED VALUE, GAPS AND FUTURE DIRECTIONS
Ali Si-Mohammed, PharmD, PhD -CHU Dijon, France
High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance
Roberta Gagliardini, MD - Lazzaro Spallanzani National Institute For Infectious Diseases Irccs, Rome, Italy
18:30 CEST
Poster viewing session 1 (odd numbers)
Day 2 - Thursday, 29 October 2020
Session 3: Resistance to Long-Acting Antivirals - 14:00
14:00 CEST
Resistance to Long-Acting Antivirals
14:15 CEST
Patients with Poor or Good Adherence: Who Will Benefit More from Long Acting Therapy?
Abstract - Driven Presentations
Emergence and Persistence of Integrase Mutation T97A Selected by Dolutegravir
Kristi Huik - HIV Dynamics and Replication Program, NCI, NIH, USA
Evaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains
Daniele Armenia, MD - Saint Camillus International University of Health Sciences, Italy
Long-term Bictegravir and Dolutegravir Resistance Selections Initiated with HIV-1 Containing M184V in Reverse Transcriptase
Kristen Andreatta - Gilead Sciences, USA
Industry-Sponsored Symposium - 15:35
15:35 CEST
Robust Regimens: Understanding the Role of Antiretroviral Resistance in the Management of HIV (ViiV Healthcare)
Poster Session - 16:45
16:45 CEST
Best of Posters
Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates Alessia Giannini - University Of Siena, Italy
Alessia Giannini - University Of Siena, Italy
Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry Francesco Saladini, PhD - University Of Siena, Italy
Francesco Saladini, PhD - University Of Siena, Italy
Two-drug regimen (2DR) for initial HIV treatment? – Lessons learned from 20 years RESINA cohort
Nadine Lübke- University of Düsseldorf, Germany
17:15 CEST
Guided Poster Tours - 4 parallel sessions
Topic 1: Epidemiology / Viral Spread
Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019
Claudia Alteri, PhD - University Of Milan, Italy
Transmitted drug resistance to integrase based first-line HIV antiretroviral treatment in the MeditRes HIV collaboration
Federico García - Hospital Universitario San Cecilio, Spain
Exploring Molecular Characteristics and Evolutionary Dynamics of the HIV-1 Epidemic in Montenegro Through Phylogenetic Analyses
Snezana Dragas, PhD - Clinical Centre , Clinic For Infectious Disease, Montenegro
Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union
Ekaterina Ozhmegova, MD - Gamaleya National Research Center Of Epidemiology And Microbiology, Russia
Topic 2: Clinical management
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M Study
Paul D. Benn - ViiV Healthcare, UK
Short- and long-term direct medical costs of late and very late HIV presentation
Lisbeth Versteegh - Erasmus MC, the Netherlands
Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018
Andrea De Vito, MD - University Of Sassari, Italy
Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
Yagai Bouba, MSc - University of Rome "Tor Vergata", Italy
Topic 3: Resistance
DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
Jean van Wyk, MB,ChB - Viiv Healthcare, UK
Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 Study
Cindy Vavro - ViiV Healthcare, USA
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
Henri Jullien - Syneos Health, France
In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
Federica Giammarino, MD - University Of Siena, Italy
Topic 4: HIV-DNA
Detection in HIV Proviral DNA of Drug Resistance Mutations in Patients with Low Permanent Viral Loads
Pablo Ferrer - Hospital Clinico Universidad De Chile, Chile
HIV-DNA Decay in Art-Native Patients Staring a DTG-Based Dual VS Triple Therapy
Francesca Lombardi - Università Cattolica Del Sacro Cuore, Italy
Role of Analitical Treatment Interruption on HIV Peripheral Reservoir Diversification
Claudia Alteri, PhD - University Of Milan, Italy
Similar levels of HIV-DNA and residual viremia are found in virologically suppressed individuals who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafe
Maria Mercedes Santoro - University of Rome "Tor Vergata", Italy
18:00 CEST
Poster viewing session 2
Satellite: Management of the COVID 19 Pandemic in Europe -
Moderator
Roger Paredes
University of Cambridge, UK
20:05 CEST
Diagnostics
20:35 CEST
Clinical relevance of diagnostic testing
20:50 CEST
Abstract-Drive Presentation:
Comprehensive assessment of SARS-CoV-2 key genetic elements single or in clusters underlying geographically-dependent genetic evolutionary adaptation and their impact on drugs binding affinity and immune escape
Mohannad Alkhatib, MB -Universta Di Roma Tor Vergata, Italy
Day 3 - Friday, 30 October 2020
Session 4: Management of Viral Hepatitis - 14:00
Anna Maria Geretti, MD, PhD, FRCPath
14:00 CEST
Treatment of Hepatitis B for HIV Clinicians
University of Rome, Italy / King's College London, United Kingdom
14:15 CEST
Hepatitis C Resistance: Pro-Con Debate
14:45 CEST
HCV Nextstrain - a phylogenetic tool to monitor HCV drug resistance and transmission
Abstract - Driven Presentations
Molecular analysis of HCV subtype 3a dispersal patterns among inmates in Greece: HCV transmissions are not related to incarceration
Evangelia-Georgia Kostaki, PhD - Medical School, National and Kapodistrian University of Athens, Greece
Characterization and Resistance Profile of “Unusual” Hepatitis C Virus (HCV) Subtypes in Italy
Velia Chiara Di Maio, MD - University Of Rome Tor Vergata, Italy
Highly sensitive digital droplet PCR assay allows to reveal cryptic HBV replication in anti-HBc positive/HBsAg negative patients with HIV infection.
Lorenzo Piermatteo, MD - "Tor Vergata" University Of Rome, Italy
Session 5: What's in the Pipeline? Presentations from Scientists in the Industry -
Hanneke Schuitemaker, PhD
Chair
16:05 CEST
Presentation
16:15 CEST
Presentation
Viral Vaccine Discovery and Translational Medicine, Janssen, The Netherlands
16:25 CEST
Presentation
16:35 CEST
Presentation
Session 6: PrEP and Resistance -
Chair
Stephan Dressler, MD, PhD
Freie Universitaet Berlin, German
17:15 CEST
Overview of the current situation regarding PrEP and resistance
17:30 CEST
Round Table Discussion: Challenges to Widespread PrEP in Europe
Overview
Welcome
Founded eighteen years ago as the European HIV Resistance Workshop, this meeting has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, and HCV infections throughout Europe.
In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.
Program Chairs 2020
General Information
COVID-19 Update
Responding to the changing COVID-19 situation throughout Europe, the European Meeting on HIV & Hepatitis 2020 was held as a completely virtual meeting. In this way, the program was delivered safely and conveniently.
We are available to answer any questions or concerns that you may have about your participation at the European Meeting on HIV & Hepatitis. For more information, please contact Magdalena Pawlowska at magdalena@amededu.com
To stay updated on developments about this meeting, make sure that you are signed up for our newsletter.
We are available to answer any questions or concerns that you may have about your participation at the European Meeting on HIV & Hepatitis. For more information, please contact Magdalena Pawlowska at magdalena@amededu.com
To stay updated on developments about this meeting, make sure that you are signed up for our newsletter.
Accreditation
An application has been made to the UEMS EACCME® for CME accreditation of this event.
Meeting Objectives
This meeting aims to:
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV, and HCV
- Integrate the latest scientific results into their daily clinical care to improve the quality of life of individuals living with hepatitis/HIV
- Recognize future challenges in the screening, monitoring, and diagnosis of patients living with HIV/HBV- or HCV and develop new concepts for research and care strategies
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV, and HCV
- Integrate the latest scientific results into their daily clinical care to improve the quality of life of individuals living with hepatitis/HIV
- Recognize future challenges in the screening, monitoring, and diagnosis of patients living with HIV/HBV- or HCV and develop new concepts for research and care strategies
Practical Information
Certificate of Attendance
A certificate of attendance was sent to participants that successfully completed the program and post-meeting survey.
Language
The official language of the meeting was English
Translation was not provided.
Translation was not provided.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the meeting is finished, provided that the speaker has given their permission to do so.
Committees
The members of the Program Committee assist the Organizing Committee by providing them with suggestions for the scientific program. In addition, they participate in reviewing abstracts and play an active role during the meeting as moderators and/or chairs of sessions.
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the meeting, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
- Carlos Beltran, MD - Chilean AIDS Group, Chile
- Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia
- Rolf Kaiser, PhD - University of Cologne, Germany
- Leon Kostrikis, PhD - University of Cyprus, Cyprus
- Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, UK
- Monique Nijhuis, PhD - University Medical Centre Utrecht, the Netherlands
- Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia
- Gary Rubin, MD - University of Toronto, Canada
- Anders Sönnerborg, MD, PhD - Karolinska Institut, Sweden
- Jan Albert, MD - Karolinska Institute, Sweden
- Janusz Stanczak, PhD - University of Warsaw, Poland
- David van de Vijver, PharmD PhD - Erasmus University Rotterdam, the Netherlands
- Hauke Walter, MD - Medizinisches Labor Stendhal, Germany
- Maurizio Zazzi, PhD - University of Siena, Italy
- Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland
- Maria Santoro, MD - University of Rome "Tor Vergata", Italy
Support
Platinum Level
Supporter Level
Endorsers
Language
Related Programs
